{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"}],"units":"Participants"}],"description":"Events of Thrombosis, Hypersensitivity and ALP will be tabulated.","groups":[{"description":"Patients receive belinostat IV over 30 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Belinostat / Enzyme Inhibitor Therapy)"}],"paramType":"NUMBER","populationDescription":"18 patients with Epithelial ovarian cancer (EOC) and 14 patients with Micro-papillary ovarian tumor (LMP)","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Number of Grade 3 Adverse Events Using the National Cancer Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0","type":"SECONDARY","unitOfMeasure":"events"}